Publications by authors named "Nicholas J Slipek"

Claim this Profile
I
Installation of dominant-negative mutations in and via base editing in primary T cells.
Bryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, Joseph G Skeate, Ethan M Niemeyer

Mol Ther Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancers.
Matthew J Johnson, Darin Sumstad, Timothy D Folsom, Nicholas J Slipek, Anthony P DeFeo

Cytotherapy· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Installation of Dominant-Negative Mutations in and via Base Editing in Primary T Cells.
Bryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, Joseph G Skeate, Ethan M Niemeyer

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Singular Base Editing Platform for Polyfunctional Multiplex Engineering of Immune Cells.
Joseph G Skeate, Nicholas J Slipek, Walker S Lahr, Shambojit Roy, Bryce J Wick

bioRxiv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.
Minjing Wang, Joshua B Krueger, Alexandria K Gilkey, Erin M Stelljes, Mitchell G Kluesner, Nicholas J Slipek

J Immunother Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates.
Matthew J Johnson, Anthony P DeFeo, Nicholas J Slipek, Timothy D Folsom, Tom Henley

J Vis Exp· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.
Beau R Webber, Matthew J Johnson, Joseph G Skeate, Nicholas J Slipek, Walker S Lahr

Nat Biomed Eng· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders.
Evan W Kleinboehl, Kanut Laoharawee, Jacob D Jensen, Joseph J Peterson, Nicholas J Slipek

Mol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.
Joseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, Bryan J Jones, Bryce J Wick

Mol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage Disorders.
Kanut Laoharawee, Evan W Kleinboehl, Jacob D Jensen, Joseph J Peterson, Nicholas J Slipek

bioRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing.
Minjing Wang, Joshua B Krueger, Alexandria K Gilkey, Erin M Stelljes, Mitchell G Kluesner, Nicholas J Slipek

bioRxiv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.
Douglas C Palmer, Beau R Webber, Yogin Patel, Matthew J Johnson, Christine M Kariya, Nicholas J Slipek

Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes.
Kanut Laoharawee, Matthew J Johnson, Walker S Lahr, Christopher J Sipe, Evan Kleinboehl, Nicholas J Slipek

Int J Mol Sci· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells.
Mitchell G Kluesner, Walker S Lahr, Cara-Lin Lonetree, Branden A Smeester, Xiaohong Qiu, Nicholas J Slipek

Nat Commun· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implication of in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma.
Branden A Smeester, Garrett M Draper, Nicholas J Slipek, Alex T Larsson, Natalie Stratton

Mol Cancer Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma.
Branden A Smeester, Nicholas J Slipek, Emily J Pomeroy, Kanut Laoharawee, Sara H Osum

Bone· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.
Branden A Smeester, Nicholas J Slipek, Emily J Pomeroy, Heather E Bomberger, Ghaidan A Shamsan

Oncogene· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.
Beau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, Matthew J Johnson, Emily J Pomeroy, Nicholas J Slipek

Nat Commun· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.
Beau R Webber, Cara-Lin Lonetree, Mitchell G Kluesner, Matthew J Johnson, Emily J Pomeroy, Nicholas J Slipek

Nat Commun· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CRISPR/Cas9-Based Positive Screens for Cancer-Related Traits.
Nicholas J Slipek, Jyotika Varshney, David A Largaespada

Methods Mol Biol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis